Telotristat etiprate + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Carcinoid Syndrome

Conditions

Carcinoid Syndrome

Trial Timeline

Mar 11, 2014 → Mar 29, 2016

NCT ID

NCT02063659

About Telotristat etiprate + Placebo

Telotristat etiprate + Placebo is a phase 3 stage product being developed by Lexicon Pharmaceuticals for Carcinoid Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02063659. Target conditions include Carcinoid Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02063659	Phase 3	Completed	Mar 11, 2014	Mar 29, 2016	Carcinoid Syndrome
NCT01456052	Phase 2	Completed	Jan 30, 2012	Sep 3, 2013	Ulcerative Colitis

Competing Products

20 competing products in Carcinoid Syndrome

See all competitors

Product	Company	Stage	Hype Score
Ramucirumab + Somatostatin Analog	Eli Lilly	Phase 2	52
Pasireotide	Novartis	Phase 1	33
Pasireotide + Octreotide	Novartis	Phase 3	77
Pasireotide (SOM230)	Novartis	Phase 2	52
Octreotide + Placebo + Everolimus	Novartis	Phase 3	77
Lutathera	Novartis	Phase 2	52
EPO906 epothilone B	Novartis	Phase 2	52
Panitumumab	Amgen	Phase 2	51
Axitinib	Pfizer	Phase 2	51
Lanreotide + Placebo (for sunitinib) + Sunitinib	Pfizer	Phase 2	51
Nivolumab + Cabozantinib	Bristol Myers Squibb	Phase 2	51
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatin	Sanofi	Phase 2/3	64
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)	Ipsen	Phase 3	74
lanreotide (Autogel formulation)	Ipsen	Approved	82
Lanreotide + Placebo	Ipsen	Phase 3	74
BIM 23A760	Ipsen	Phase 2	49
Randomized: 40 mg Paltusotine + Randomized: 80 mg Paltusotine	Crinetics Pharmaceuticals	Phase 2	47
Paltusotine + Placebo	Crinetics Pharmaceuticals	Phase 3	72
Telotristat etiprate + Placebo-matching telotristat etiprate	Lexicon Pharmaceuticals	Phase 3	72
Telotristat etiprate	Lexicon Pharmaceuticals	Phase 3	72

Other Products from Lexicon Pharmaceuticals

Sotagliflozin + PlaceboPhase 3

Telotristat etiprate + Placebo-matching telotristat etipratePhase 3

Telotristat etipratePhase 3

Sotagliflozin Low Dose + Sotagliflozin High DosePhase 3

250 mg LX1033 tablets + Placebo tabletPhase 2